Abstract

We report a case of rapid resolution of Coronary Artery Spasm (CAS) and improvement of systolic heart failure by antirejection therapy with methylprednisolone in the setting of acute Orthotopic Heart Transplant (OHT) rejection. The proposed mechanism of action is reduced microvascular inflammation from steroid therapy resulting in enhanced vasomotor response, resolution of coronary artery spasm, and improved hemodynamic. The case report has treatment implications for patients in acute OHT rejection with coronary artery spasm. Antirejection therapy with steroid may be helpful in treating life threatening cardiac conditions in patients with acute OHT rejection and coronary artery spasm.

Keywords: Antibody mediated rejection; Coronary artery spasm; Orthotopic heart transplant; Systolic heart failure

Abbreviations: AMR: Antibody Mediated Rejection; CAS: Coronary Artery Spasm; HLA: Human Leukocyte Antigen; LAD: Left Anterior Descending; OHT: Orthotopic Heart Transplant; TIMI: Thrombolysis in Myocardial Infarction

Introduction

Coronary Artery Spasm (CAS) is defined as vasoconstriction of epicardial coronary artery causing vessel narrowing or occlusion [1]. CAS has been described as an early stage of cardiac allograft vasculopathy [2]. CAS involves an imbalance of autonomic nervous system, endothelial dysfunction, and abnormal smooth muscle reactivity [1]. In acute Orthotopic Heart Transplant (OHT) rejection, in addition to attenuated nitric oxide production [3], microvascular inflammation [4] may also be a contributor to CAS. In this case report, we describe the pathophysiology and clinical presentation of a unique case of CAS, in acute OHT rejection, which partially improved with sublingual nitroglycerin but completely resolved after antirejection therapy with steroid within 24 h.

Case Presentation

29 year-old male with history of dilated cardiomyopathy and OHT two years prior, who complained of dyspnea on exertion, orthopnea, and paroxysmal nocturnal dyspnea for one week. Patient underwent outpatient left and right cardiac catheterization and showed diffuse mid Left Anterior Descending (LAD) narrowing estimated at 75% throughout (Figure 1) with diagonal involvement, which were not present one year prior. After administration of sublingual nitroglycerin, the stenoses marginally improved (Figure 2) but Thrombolysis in Myocardial Infarction (TIMI) 2 slow flow throughout the coronary bed remained. The Left Ventricular End Diastolic Pressure (LVEDP) was 26 mmHg. Given the patient’s history and invasive study findings, he was directly admitted to the cardiac care unit for suspected acute OHT rejection. While waiting for test results to confirm rejection, patient was started on antirejection immunosuppressive therapy including intravenous methylprednisolone [5-7]. On the following day, patient underwent repeat left cardiac catheterization which showed resolution of the LAD and diagonal stenoses (Figures 3 and 4), normalization of coronary flow (TIMI 3), and significantly improved LVEDP of 14 mmHg. Laboratory studies collected on admission revealed the presence of new human leukocyte antigen HLA-DQ, HLA-DQ7, and anti-complement C1q antibodies indicating that the patient had acute antibody mediated rejection (AMR). Echocardiogram showed a reduction in left ventricular ejection fraction from 75%, one month prior, to 45% with elevated filling pressures. Individualized treatment plan for AMR was escalated to include plasmapheresis [5,8], intravenous immunoglobulin [5,8], and antithymocyte globulin [9,10] infusion. Patient’s clinical status improved with OHT antirejection therapy and was discharged home on hospital day ten.

Discussion

Coronary Artery Spasm (CAS) in OHT has been reported as early as 1981 [11], Buda induced CAS in an OHT patient with intravenous ergonovine maleate. Subsequent reports demonstrated the resolution of CAS in OHT patients by intracoronary nitroglycerin [12,13] and sublingual nitroglycerin [14]. However, we present the first case of CAS in the setting of acute OHT rejection with complete resolution of CAS after initiation of antirejection therapy with methylprednisolone. Secondly, the physiologic response to antirejection therapy was immediate, within 24 h, as evidenced by resolution of CAS and normalization of LVEDP.

The pathophysiology of CAS is complex and involves an imbalance of autonomic nervous system, endothelial dysfunction, and abnormal smooth muscle reactivity [1]. However, patients with OHT are derenervated suggesting that autonomic nervous system and cardiac innervation are not essential mechanisms in all CAS [11-14]. At the source are credited.
molecular level, mediators including acetylcholine, serotonin, and histamine trigger the release of nitric oxide by endothelin resulting in vasodilation [1]. On the other hand, the same mediators stimulate vascular smooth muscle cells resulting in vasoconstriction. With endothelial dysfunction, the balancing mechanism is impaired and results in vasoconstriction and spasms [1].

Molecular pathways involved in CAS in acute OHT rejection are even more complex than CAS in non-transplanted patients. Factors contributing CAS in acute OHT rejection include complement deposition, impaired endothelial adhesion to extracellular matrix, lower nitric oxide production, and reduction of endothelium dependent relaxation to acetylcholine [3]. Furthermore, endothelial Notch ligand Dll4 is upregulated in AMR which induces macrophage polarization into a pro-inflammatory state and intravascular macrophage infiltrate. The overall result is microvascular inflammation [4].

Previously, Schlaifer and Mills compared the vasomotor response in epicardial coronary artery before and after immunosuppression with steroid in acute OHT rejection [15]. Impaired coronary blood flow response to acetylcholine was found at baseline in all nine subjects. More importantly, after three days of intense intravenous methylprednisolone therapy, repeat invasive study showed a trend towards greater dilation of epicardial coronary artery with administration of nitroglycerin. The study demonstrated that steroid therapy in acute OHT rejection reduced microvascular inflammation and improved epicardial coronary artery vasomotor response, which explains our observations in the presented case.

The current case report may also have important treatment implications in patients with CAS who are in acute OHT rejection. CAS can cause life threatening conditions including coronary artery occlusion, coronary ischemia, ventricular fibrillation, cardiac arrest [11,14,16], and in our case acute decompensated systolic heart failure [17,18]. The CAS marginally improved with sublingual nitroglycerin but did not achieve complete distal flow normalization until patient received antirejection immunosuppressive therapy for acute OHT rejection with methylprednisolone. This suggests that patients in acute OHT rejection and severe CAS, treatment with vasodilators may not be adequate and may require the initiation of antirejection therapy for complete resolution.

**Conclusion**

We report the first case of CAS in acute OHT rejection with complete resolution of CAS and improved systolic heart failure by antirejection therapy with methylprednisolone. Furthermore, treatment response was immediate, within 24 h. The proposed mechanism of action is reduced microvascular inflammation from steroid therapy resulting in enhanced vasomotor response, resolution of CAS, and improved
hemodynamics. This case report suggests important treatment implications in patients with CAS and acute OHT rejection, especially if patient is in life threatening clinical situations including coronary artery occlusion, coronary ischemia, severe heart failure, or fatal arrhythmias. Early initiation of steroid therapy may help to improve CAS and could potentially serve as a lifesaving intervention.

References